Bausch Health Companies Inc. (TSX:BHC)
Market Cap | 3.45B |
Revenue (ttm) | 13.44B |
Net Income (ttm) | 133.66M |
Shares Out | n/a |
EPS (ttm) | 0.36 |
PE Ratio | 25.78 |
Forward PE | 1.68 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 293,423 |
Average Volume | 383,369 |
Open | 9.35 |
Previous Close | 9.34 |
Day's Range | 9.03 - 9.35 |
52-Week Range | 5.91 - 13.74 |
Beta | 0.43 |
RSI | 43.66 |
Earnings Date | Oct 29, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appea...

Bausch Health to Announce Third Quarter 2025 Results on October 29
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025....
Bausch Health (BHC) Launches OraTalks Podcast to Address Dental Industry Issues
Bausch Health (BHC) Launches OraTalks Podcast to Address Dental Industry Issues

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.
BHC Makes Notable Cross Below Critical Moving Average
In trading on Thursday, shares of Bausch Health Companies Inc (Symbol: BHC) crossed below their 200 day moving average of $6.50, changing hands as low as $6.40 per share. Bausch Health Companies Inc s...
Bausch + Lomb Breaks Below 200-Day Moving Average - Notable for BLCO
In trading on Thursday, shares of Bausch + Lomb Corporation (Symbol: BLCO) crossed below their 200 day moving average of $14.65, changing hands as low as $14.14 per share. Bausch + Lomb Corporation sh...
Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan
Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan
Bausch Health: Repricing Continues As Deleveraging Gains Traction
Bausch Health (BHC) Completes Acquisition of DURECT Corporation
Bausch Health (BHC) Completes Acquisition of DURECT Corporation

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Ameri...

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophth...
Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news
Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin ...
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System | BHC Stock News

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aest...

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...
Carl Icahn's Complete Divestment from Bausch Health Companies Inc
Carl Icahn's Complete Divestment from Bausch Health Companies Inc

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...

A Look Into Bausch Health Companies Inc's Price Over Earnings
In the current session, the stock is trading at $7.81, after a 0.26% increase. Over the past month, Bausch Health Companies Inc. (NYSE: BHC) stock increased by 14.81% , and in the past year, by 32.32...

Bausch + Lomb board members resign after Icahn agreement ends
Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

Alembic Pharma shares jump over 2% as USFDA approves Tretinoin Cream USP
Shares of Alembic Pharmaceuticals gained over 2% on Monday, August 19, after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...